Talus Bio Announces New Collaboration with PRISM BioLab to Discover Novel Modulators of Transcription Factor and Protein-Protein Interaction Targets
Talus Bioscience, Inc. (“Talus Bio”), an AI-enabled regulome therapeutics company, today announced a strategic collaboration with PRISM BioLab Co., Ltd. (“PRISM”) to accelerate the discovery and development of novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets. The collaboration combines Talus Bio’s pioneering regulome profiling and AI-guided drug discovery platform with PRISM’s innovative chemistry.
